Raloxifene in clinical practice. Results of the non-interventional study CORAL (Compliance with RALoxifene);Raloxifen v klinické praxi. Výsledky neintervenč ní klinické studie CORAL (Compliance with RALoxifene)

Vnitrni Lekarstvi

Volumn 54, Issue 3, 2008, Pages 217-224

  Rosa, Jan ^a   Vanuga P ^b   Payer, J ^c   Svobodnik A ^d  

^a Diagnosticke centrum Mediscan Czech   (Czech Republic)

^b Národný Endokrinologický a Diabetologický Ústav l'Uboch a   (Slovenia)

^c V Interná Klinika Lekárskej Fakulty UK a FNsP Bratislava   (Slovenia)

^d MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Compliance; Non interventional study; Osteoporosis; Raloxifene

Indexed keywords

RALOXIFENE;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED STUDY; DENSITOMETRY; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MULTICENTER STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; QUALITY OF LIFE; QUESTIONNAIRE;

EID: 42449134558     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. WHO Technical Series Report 843, World Health Organisation, Geneva, 1994.
2. Štěpán J, Havelka S, Kamberská Z et al. Epidemiologie der Osteoporose in der Tschechischen Republik. J Miner Stoffwechs 2002; 9: 7-13.
3. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-795.
4. Melton LJ 3rd, Chrischilles EA, Cooper C et al. Perspective. How many women have osteoporosis? J Bone Miner Res 1992; 7: 1005-1010.
5. Rosa J. Raloxifen - lékový profil. Remedia 2007; 17: 430-436.
6. Lufkin EG, Wong M, Deal C. The role of selective estrogen receptor modulators in the prevention and treatment of postmenopausal osteoporosis. Rheum Dis Clin North Am 2001; 27: 163-185.
7. Delmas PD, Genant HK, Crans CC. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003; 33: 522-532.
8. Cauley JA, Norton L, Lippman ME et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treatment 2001; 65: 125-134.
9. Martino S, Cauley JA, Barrett-Connor E et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751-1761.
10. Baker VL, Ulrich U, Taylor RN. Estrogen replacement and alternatives for the prevention and treatment of osteoporosis. Curr Probl Obstet Gynecol Fertil 1999; 22: 77-119.
11. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997; 102: 43-49.
12. Fawcett J. Compliance: definitions and key issues. J Clin Psychiatry 1995; 56(Suppl 1): 4-8.
13. Melnikow J, Kiefe C. Patient compliance and medical research: issues in methodology. J Gen Intern Med 1994; 9: 96-105.
14. Delmas PD, Bjarnason NH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-1647.
15. Ettinger B, Black DM, Mitlak BH et al (for the MORE study group). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999; 282: 637-645.
16. Walsh BW, Kuller LH, Wild RA et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445-1451.
17. Davies GS, Huster WJ, Shen W et al. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause 1999; 6: 188-195.
18. Cummnings SR, Eckert S, Krueger KA et al (for the MORE study group). The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999; 281: 2189-2197.
19. Davies GC, Huster WJ, Lu Y et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999; 93: 558-565.
20. Silverman SL, Minshall ME, Shen W et al. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis. Resu)lts from the MORE study. Arthr Rheum 2001; 44: 2611-2619.
21. Houpt LS, Minshall ME, Shen W et al. Study completer analysis of quality of life results from a clinical trial of a selective estrogen receptor modulator, raloxifene, and hormone replacement therapy. Calcified Tissue Int 1997; 61: S503.
22. Voss S, Hunter MS, Bäckström T et al. Comparison of raloxifene and contiunous combined HRT - effects of compliance on quality of life. Osteoporosis Int 2000; 11(Suppl 5): S5.
23. Haynes RB, Sackett DL, Gibson ES et al. Improvement of medication compliance in uncontrolled hypertension. Lancet 1976; 1: 1265-1268.
24. Yood RA, Srinivas Emani S, Reed JI et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003; 14: 965-968.
25. Turbi C, Herrero-Beaumont G, Acebes JC et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 2004; 26: 245-256.
26. Lips P, van Schoor NM. Quality of life in patients with osteoporosis. Osteoporos Int 2005; 16: 447-455.
27. Caro JJ, Ishak KJ, Huybrechts KF et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15: 1003-1008.